Use of co-primary outcomes for trials of antimicrobial stewardship interventions

David Gillespie1, Nick A Francis2, Enitan D Carrol3, Emma Thomas-Jones1, Christopher C Butler4, Kerenza Hood1

1 – Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, U.K.
2 – Division of Population Medicine, School of Medicine, College of Biomedical and Life Sciences, Cardiff University, Cardiff, U.K.
3 – University of Liverpool Institute of Infection and Global Health, Liverpool, U.K.
4 - Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, U.K.

Type of article: Comment

Word count: 734 words

Antimicrobial resistance (AMR) is a major public health threat that will cause an estimated 10 million deaths worldwide by 2050. [1] Because antimicrobial use drives selection and transmission of AMR, [2, 3] there is an urgent need to continue to develop, evaluate, and implement effective, evidence-based antimicrobial stewardship (AMS) interventions that safely reduce antimicrobial use in both primary and secondary healthcare. [4, 5]

AMS interventions can benefit individual patients, but are often viewed as trading potential increased short-term individual disbenefit for long-term societal gain, [6] and so some consider them ‘bedside rationing’. [7] The need to consider the ethical implications of AMS programmes, and acceptable trade-offs, will increase as antimicrobial prescribing is reduced and programmes are investigated among patients with an increased chance of benefit from antimicrobials.

While there is a clear need to ensure that reductions in antimicrobial use are not at the expense of patient outcomes, most current research considers these outcomes separately. AMS studies are therefore generally powered on only one of these aspects (typically antimicrobial use), and as a result,
are frequently underpowered to detect clinically meaningful differences in important clinical secondary outcomes, and do not pre-specify whether between-group differences in clinical outcomes will be investigated under superiority, non-inferiority, or equivalence hypotheses.

This article describes the use of co-primary outcomes as a solution to this problem, presents two examples of co-primary outcomes in AMS intervention trials, and argues for their routine use in AMS intervention evaluations.

Co-primary outcomes involve the use of two or more primary outcomes, where rejecting both null hypotheses is necessary for the intervention to be declared effective. This contrasts with studies that have multiple primary outcomes where rejecting the null hypothesis for at least one (i.e. alternative primary outcomes) determines effectiveness. The use of co-primary outcomes in AMS intervention research encourages researchers to pay close attention to both antimicrobial use and patient-relevant measures (e.g. recovery from illness, safety outcomes), ensuring the study is adequately designed to simultaneously answer both questions. Thus, any reduction in antibiotic use must be judged in conjunction with any negative impact on patient recovery. Additional sample size considerations for trials with co-primary outcomes include the assumed correlation between outcomes and the overall power of the study. When outcomes are completely independent, the overall power (to detect similar effect sizes in both outcomes) is the product of the power for each individual outcome, and only when they are perfectly correlated is the overall power unaffected. [8]

The PACE study (General practitioner use of a C-reactive protein point-of-care test to help target antibiotic prescribing in patients with acute exacerbations of chronic obstructive pulmonary disease) determined the effectiveness of C-reactive Protein (CRP) point-of-care testing on safely reducing antibiotic use in patients presenting in primary care with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD). [9] The study used two co-primary outcomes: i.) Antibiotic use for AECOPD within the first four-weeks post-randomisation; ii.) COPD health status, as measured by the COPD Clinical Questionnaire at two-weeks post-randomisation. These co-primary outcomes were
investigated for superiority and non-inferiority respectively. The study aimed to recruit 650 participants in order to achieve between 81% and 90% power to detect a 20% absolute difference in antibiotic use, and a COPD health status that is no worse (with a non-inferiority margin of 0.3).

The BATCH study (Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection) is investigating the effect of procalcitonin-guided management on antibiotic use in children with severe bacterial infection. [10] The co-primary outcomes for the study are i.) Number of days of intravenous (IV) antibiotic therapy, and; ii.) Safety (comprising unscheduled admissions/re-admissions; re-treatment for same condition within 7 days of stopping IV antibiotics; mortality). The study aims to recruit 1942 participants to achieve between 99% power to detect a decrease in antibiotic duration and 90% power to test non-inferiority in safety. Assuming that the antibiotic use and safety primary outcomes are independent, this will give at least 89% power for the combined analysis.

Reducing antimicrobial use is essential to preserving antimicrobial effectiveness, but should not harm patients in the process. AMS intervention evaluations must consider the clinical implications of changed antimicrobial use, and the use of co-primary outcomes ensures that both use and safety outcomes are considered jointly. Researchers in this field are encouraged to consider the use of co-primary outcomes, and research funders should consider mandating this dual focus when commissioning AMS intervention studies.

**Acknowledgements**

The authors declare no competing interests.

The PACE and BATCH studies were funded by the National Institute of Health Research Health Technology Assessment (PACE: HTA project reference 12/33/12 ISRCTN 24346473; BATCH: HTA project reference 15/188/42 ISRCTN 11369832). The work was undertaken with the support of the
UKCRC registered Centre for Trials Research. Infrastructure funding from Health and Care Research Wales and Cancer Research UK is gratefully acknowledged.

DG is a Research Fellow in Statistics at the Centre for Trials Research at Cardiff University. NAF is a General Practitioner and Clinical Reader at the Division of Population Medicine at Cardiff University. EDC is a Professor and Chair in Paediatric Infection at the Institute of Infection and Global Health at University of Liverpool, and Honorary Consultant in Paediatric Infectious Diseases and Immunology at Alder Hey Children's NHS Foundation Trust. ETJ is a Research Fellow at the Centre for Trials Research at Cardiff University. CCB is an NIHR Senior Investigator and Director of the Primary Care and Vaccines Clinical Trials Cooperative and the NIHR Community Medical Technology and Invitro-diagnostics Cooperative, University of Oxford. KH is a Health & Care Research Wales Senior Research Leader and Director of the Centre for Trials Research.

References


